Job Description

About the Company

The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients.

Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options.

We are now looking for a highly motivated Postdoctoral Researcher in the Drug Metabolism and Pharmacokinetics (DMPK) section of our Nonclinical Development department (2 years).

Job Responsibilities

• Establish and evaluate New Approach Methodologies (NAMs) such as advanced in vitro hepatic systems to improve the prediction of human clearance, with a particular focus on low-turnover compounds.
• Compare intrinsic clearance data generated in conventional systems, such as human liver microsomes and cryopreserved hepatocytes, with data from more complex liver-cell models such as HepaRG, HepatoPac, TruVivo or related systems.
• Develop and apply robust LC-MS/MS bioanalytical methods to quantify parent compound depletion and, where appropriate, metabolite formation in those assays.
• Investigate the impact of nonspecific binding, compound stability, incubation recovery and free concentration on the interpretation of clearance data and support in vitro–in vivo extrapolation in collaboration with DMPK modelers.
• Assess the suitability of advanced hepatic systems for drug-metabolizing enzyme phenotyping in comparison with human liver microsomes, integrating metabolite identification where appropriate.
• Document, analyze and present experimental results in multidisciplinary project teams, and contribute to scientific reports, internal presentations, conference communications and peer-reviewed publications.

Candidate’s Requirements

• PhD in pharmaceutical sciences, analytical chemistry, biochemistry, biology, pharmacology or a related discipline, with solid scientific training and a strong interest in applying experimental and analytical skills to DMPK questions.
• Hands-on experience with cell culture and LC-MS/MS bioanalysis is required; experience with high-resolution MS and/or metabolite identification is an advantage.

• Experience with in vitro ADME/DMPK assays, such as microsomal or hepatocyte stability, protein binding, drug-metabolizing enzyme phenotyping, is desirable.
• Good understanding of drug metabolism, hepatic clearance mechanisms, enzyme phenotyping and in vitro–in vivo extrapolation, or strong motivation to develop expertise in these areas.

• Proactive, collaborative and reliable personality with strong analytical thinking, excellent organizational and communication skills, and the ability to work effectively in a multidisciplinary and multicultural environment.
• Excellent knowledge of English.

Work Location: Allschwil – Basel Area
Country: Switzerland
Business Area: Non Clinical Development
Schedule: Fulltime
Job Type: Postdoc Programme - 2 years
Job ID: 4809

At Idorsia, we harness the power of difference, authenticity and inclusion to achieve business success. We are committed to fostering respect, fairness and equal opportunities for all job applicants and all our employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sexual orientation, gender identity, age, national origin, or protected veteran status and will not be discriminated against based on disability.

Please be informed that if you are selected for this position, your employment will be subject to a pre-employment background screening process, of which you will be informed in greater detail in due course.

Idorsia operates a strictly controlled list of preferred recruitment partners. For those partners who have no valid, signed Master Service Agreement in place with Idorsia, please note that all unsolicited resumes, CVs, anonymous profiles, or any other candidate details submitted through our website or to personal e-mail accounts of employees of Idorsia Pharmaceuticals (including any of its subsidiaries, affiliates or related companies) are considered the property of Idorsia Pharmaceuticals and are not subject to payment of any form of introduction, placement or referral fees.